New heart valve device offers hope for High-Risk patients
NCT ID NCT04982588
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new heart valve device, the Medtronic CoreValve Evolut PRO, in 52 Chinese patients with severe aortic stenosis who are at high risk for open-heart surgery. The device is inserted through a catheter, avoiding major surgery. Researchers are checking how safe and effective it is by measuring death rates and valve function at 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Medtronic CoreValve Evolut PRO heart valve device
- What this could lead to
- If successful, this could provide a safer, less invasive option for Chinese patients with severe aortic stenosis who are too high-risk for open-heart surgery.
- What could go wrong
- This is a small, early-stage study with only 52 participants, so results may not apply to everyone. Risks include bleeding, stroke, or kidney injury.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE SYMPTOMATIC AORTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100000, China
-
Chinese PLA General Hospital, Chinese PLA Medical School
Beijing, Beijing Municipality, 100000, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.